Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) were up 5.5% during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $3.00 to $4.00. Morgan Stanley currently has an underweight rating on the stock. bluebird bio traded as high as $6.60 and last traded at $6.53. Approximately 3,046,105 shares changed hands during trading, a decline of 37% from the average daily volume of 4,807,327 shares. The stock had previously closed at $6.19.

Other equities analysts have also recently issued reports about the stock. StockNews.com started coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Royal Bank of Canada decreased their price target on shares of bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, SVB Leerink decreased their price target on shares of bluebird bio from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $6.75.

Get bluebird bio alerts:

Insider Transactions at bluebird bio

In other news, Director Nick Leschly sold 4,290 shares of the stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 9,506 shares of company stock worth $72,088 over the last three months. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On bluebird bio

A number of large investors have recently bought and sold shares of the stock. Inspire Investing LLC grew its holdings in bluebird bio by 3.6% in the second quarter. Inspire Investing LLC now owns 50,497 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 1,773 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in bluebird bio by 6.4% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 35,817 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 2,156 shares during the period. Captrust Financial Advisors grew its holdings in bluebird bio by 22.5% in the third quarter. Captrust Financial Advisors now owns 14,679 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 2,700 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in bluebird bio by 142.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,744 shares during the period. Finally, US Bancorp DE grew its holdings in bluebird bio by 82.9% in the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 3,847 shares during the period. 79.01% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Price Performance

The firm has a market capitalization of $541.49 million, a price-to-earnings ratio of -1.07 and a beta of 0.99. The business's fifty day simple moving average is $7.40 and its 200 day simple moving average is $6.52.

bluebird bio (NASDAQ:BLUE – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $2.25 million. bluebird bio had a negative net margin of 8,828.28% and a negative return on equity of 173.58%. Equities research analysts expect that bluebird bio, Inc. will post -4.36 earnings per share for the current fiscal year.

About bluebird bio

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Featured Articles

• Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
• High-Yield, Deep-Value Verizon Puts In A Bottom
• Should You Bet Against The Nasdaq 100 With This Inverse ETF?
• Can Coty Stock Emerge in 2023 With Upside
• Insiders Buy Archer Aviation, Is This Stock About To Take Off?
• Intuit Is About To Make a Move, But Which Way?

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.